Clover Health Investments Insider Sells Shares

Joseph Frank Oldakowski, Vice President of Finance and Controller at Clover Health Investments, Corp. (NasdaqGS: CLOV), sold 12,102 shares of the company on June 16, 2026. The shares were sold at an average price of $4.86 each, totaling $58,815. This transaction was part of a pre-arranged trading plan.

Insider Buying and Selling at Clover Health Investments, Corp.

In addition to Oldakowski's sale, several other insiders at Clover Health have recently sold shares. On June 15, 2026, Chief Legal Officer Karen Soares sold 4,681 shares at $4.61 each. Jamie Reynoso, CEO of Medicare Advantage, sold 6,350 shares at the same price on the same day. Reynoso also sold 7,289 shares on June 11 at $4.91. Conrad Wai, CEO of Counterpart Health, sold 220,426 shares on May 28 at $3.99, and Carladenise Armbrister Edwards sold 67,160 shares on May 18 at $3.42.

Other Institutional Activity in Clover Health

BlackRock, Inc. reduced its stake in Clover Health by 440,347 shares, bringing its total to 31,840,512 shares valued at about $56.04 million. Vanguard Capital Management LLC added a significant 16,982,073 shares, now holding the same amount worth approximately $29.89 million. Geode Capital Management, LLC increased its position by 264,302 shares, ending with 10,055,510 shares valued at $17.70 million. State Street Corp also boosted its holdings by 239,706 shares to a total of 9,559,889 shares worth $16.83 million. Charles Schwab Investment Management Inc. added 609,571 shares, holding 5,300,475 shares valued at $9.33 million.

Clover Health Stock Snapshot

Clover Health Investments, Corp. is trading at around $4.94 per share. The company has a market capitalization of approximately $2.6 billion and a forward P/E ratio of 49.4, indicating a high valuation relative to its earnings outlook. With a beta of 2.484, the stock is more volatile than the overall market. Over the past year, the stock has ranged from $1.58 to $5.18, with moving averages of $3.18 over 50 days and $2.69 over 200 days. The company's current ratio is 1.331, and its quick ratio is 1.207, suggesting moderate short-term financial health.

Recent Earnings

Clover Health reported revenues of approximately $2.21 billion, with a growth rate of 62%. However, the company is not yet profitable, with a net margin of -2.58% and a return on equity of -16.86%. The next earnings report is expected on August 4, 2026.

Analysts Set New Price Targets

On June 11, 2026, UBS maintained a 'hold' rating on Clover Health, setting a price target of $4.75. Earlier, on June 4, Canaccord Genuity reiterated its 'buy' rating with a target of $4.2. Overall, the consensus among analysts is a 'buy' rating, with a mean target price of $4.15, based on three different opinions.

About Clover Health Investments, Corp.

Clover Health Investments, Corp. provides Medicare Advantage plans in the United States, offering both preferred provider organization and health maintenance organization plans to eligible individuals. The company also operates Clover Assistant, a software platform that helps physicians manage chronic diseases. Founded in 2014, Clover Health is headquartered in Wilmington, Delaware, and led by CEO Andrew Toy. The company employs 724 people.

Bottom Line

Clover Health Investments, Corp. continues to attract attention from insiders and institutional investors. Recent insider sales, including those by Joseph Frank Oldakowski, reflect planned transactions rather than spontaneous market reactions. The company's stock remains volatile, with a high forward P/E ratio and a 'buy' recommendation from analysts. As always, remember that insider and institutional activities are backward-looking and may not reflect current positions.